Trial Profile
Efficacy and Safety Study of Chidamide in Patients with Refractory or Relapsed Cutaneous T-cell Lymphoma.
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 24 Apr 2016
Price :
$35
*
At a glance
- Drugs Tucidinostat (Primary)
- Indications Cutaneous T-cell lymphoma
- Focus Therapeutic Use
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
- 08 Dec 2015 Status changed from recruiting to completed, according to the results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
- 28 Mar 2010 Status changed from planning to recruiting as reported by Chinese Clinical Trial Register record.